Cargando…

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland

INTRODUCTION: Rilpivirine (RPV) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral-naïve individuals with HIV-1 viral load of <100,000 copies/ml. As transmission of the drug resistance mutations to this NNRT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parczewski, Miłosz, Urbańska, Anna, Maciejewska, Katarzyna, Witak-Jȩdra, Magdalena, Leszczyszyn-Pynka, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991831/ https://www.ncbi.nlm.nih.gov/pubmed/24746180 http://dx.doi.org/10.7448/IAS.17.1.18929

Ejemplares similares

Temporal increase in HIV-1 non-R5 tropism frequency among antiretroviral-naive patients from northern Poland
por: Parczewski, Milosz, et al.
Publicado: (2014)

The temporal increase in HIV-1 non-R5 tropism frequency among newly diagnosed patients from northern Poland is associated with clustered transmissions
por: Parczewski, Miłosz, et al.
Publicado: (2015)

Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2016)

Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2015)

Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
por: Parczewski, Milosz, et al.
Publicado: (2014)

HIV-1 Subtype D Infections among Caucasians from Northwestern Poland—Phylogenetic and Clinical Analysis
por: Parczewski, Miłosz, et al.
Publicado: (2012)

Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland
por: Parczewski, Miłosz, et al.
Publicado: (2017)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2012)

Factors Influencing Immune Restoration in People Living with HIV/AIDS
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Septic Shock Induced by Vibrio Vulnificus in Northern Poland, a Case Report
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Risk of All-Cause Mortality in HIV Infected Patients Is Associated with Clinical, Immunologic Predictors and the CCR5 Δ32 Deletion
por: Parczewski, Milosz, et al.
Publicado: (2011)

Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics
por: Parczewski, Milosz, et al.
Publicado: (2017)

Transmitted HIV drug resistance and subtype patterns among blood donors in Poland
por: Parczewski, Miłosz, et al.
Publicado: (2021)

Molecular epidemiology and HIV-1 variant evolution in Poland between 2015 and 2019
por: Serwin, Karol, et al.
Publicado: (2021)

Non-HIV-related comorbidities and uncontrolled HIV replication are independent factors increasing the odds of hospitalization due to COVID-19 among HIV-positive patients in Poland
por: Kowalska, Justyna D., et al.
Publicado: (2022)

CCR5 D32 modifies 15-year mortality risk associated with well-established clinical and immunological factors among HIV-infected patients
por: Parczewski, M, et al.
Publicado: (2010)

Hepatotropic Properties of SARS-CoV-2—Preliminary Results of Cross-Sectional Observational Study from the First Wave COVID-19 Pandemic
por: Wiśniewska, Hanna, et al.
Publicado: (2021)

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
por: Lombaard, Johan, et al.
Publicado: (2022)

Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Correction: Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
por: Pereira, Mariana, et al.
Publicado: (2023)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Transmitted drug resistance associated with transmission clusters in newly diagnosed antiretroviral-naïve patients in Northern Greece
por: Skoura, L, et al.
Publicado: (2010)

The Spectrum of Malignancies among Adult HIV Cohort in Poland between 1995 and 2012: A Retrospective Analysis of 288 Cases
por: Kowalski, Jacek, et al.
Publicado: (2015)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013)

Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV
por: Muccini, Camilla, et al.
Publicado: (2023)

Molecular Evolution and Epidemiological Characteristics of SARS COV-2 in (Northwestern) Poland
por: Serwin, Karol, et al.
Publicado: (2021)

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013
por: McFaul, Katie, et al.
Publicado: (2014)

Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China
por: Zhao, Shuai, et al.
Publicado: (2018)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia
por: Kotaki, Tomohiro, et al.
Publicado: (2015)

Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
por: Memarnejadian, Arash, et al.
Publicado: (2015)

1601. Transmitted Drug Resistance in Treatment-Naïve People Living with HIV in Costa Rica
por: Ramirez-Cardoce, Manuel, et al.
Publicado: (2023)

Prevalence and genotype distribution of human papillomavirus infection among HIV-infected men who have sex with men living in Lower Silesia, Poland
por: Biała, Martyna, et al.
Publicado: (2022)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
por: Ho, Sharlene, et al.
Publicado: (2020)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

SARS-CoV-2 Whole-Genome Sequencing by Ion S5 Technology—Challenges, Protocol Optimization and Success Rates for Different Strains
por: Szargut, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_utdrrp0dc66e5mhrqg5vj2j9fp